Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 32 (RPL23AP32)
- Target
- RPL23AP32
- Molecular classification
- Pseudogene, non-coding RNA
01
Overview
Ribosomal protein L23a pseudogene 32 (RPL23AP32) is a non-coding segment of DNA that closely resembles the protein-coding gene for ribosomal protein L23a but typically carries disabling mutations, such as premature stop codons or frameshifts, preventing it from producing a functional protein. Pseudogenes are widespread in the genome and may sometimes regulate gene expression through RNA-mediated mechanisms; however, there is no specific evidence or functional annotation for RPL23AP32, and it is not currently considered a drug target or involved in known disease mechanisms.
- Other names
- DKFZp547I014RPL23AP32
02
Mechanism of action
Not applicable; pseudogenes do not encode functional proteins and are not drug targets
03
Biological functions
Generally considered non-functional; however, pseudogenes may sometimes regulate their parent genes via mechanisms such as acting as miRNA decoys or producing small regulatory RNAsNo experimental evidence for regulatory functions specific to RPL23AP32; all functional claims pertain to pseudogenes in general
04
Disease associations
No direct evidence for RPL23AP32 in any diseaseStudies on other ribosomal protein L23a pseudogenes (e.g., RPL23AP53) suggest possible variations in expression in certain cancers, but this cannot be generalized to RPL23AP32 without specific supporting data
05
Safety considerations
Not applicable; pseudogenes like RPL23AP32 are neither therapeutic targets nor safety concerns in pharmacology
06
Interacting drugs
None known; pseudogenes are generally not targeted by drugs
07
Biomarkers
None known for RPL23AP32; other pseudogenes (e.g., RPL23AP53) are under investigation for biomarker roles in melanoma, but these findings do not extend to RPL23AP32 without further data
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 32 (RPL23AP32).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 32 (RPL23AP32).